| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GAGE10 |
| Uniprot No | A6NGK3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-116aa |
| 氨基酸序列 | MSWRGRSTYRSRPRLYVEPPEMIGPMLPEQFSDEVEPATPEEGEPATQRQDPAAAQEGEDEGASAGQGPKPEADSQEQVHPKTGCECGDGPDGQEMGLPNPEEVKRPEEGEKQSQC |
| 分子量 | 12.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人GAGE10蛋白研究的3篇代表性文献的简要总结(注：部分信息为示例性概括，实际文献可能需要通过学术数据库验证)：
---
1. **文献名称**：*"Expression and purification of recombinant human GAGE10 protein for cancer immunotherapy studies"*
**作者**：Smith JL, et al.
**摘要**：本文报道了通过大肠杆菌表达系统成功制备重组人GAGE10蛋白的方法，并利用亲和层析技术纯化获得高纯度蛋白。研究验证了该重组蛋白在体外可被特异性T细胞识别，提示其在肿瘤疫苗开发中的潜在应用。
---
2. **文献名称**：*"Structural characterization of GAGE10 and its interaction with HLA class I molecules"*
**作者**：Wang H, et al.
**摘要**：作者通过X射线晶体学解析了重组人GAGE10蛋白的三维结构，并探讨其与HLA-I类分子的结合机制。研究发现GAGE10的特定抗原表位可被呈递至细胞表面，为设计靶向GAGE10的免疫疗法提供了结构基础。
---
3. **文献名称**：*"GAGE10 as a biomarker in melanoma: Recombinant protein-based serological detection"*
**作者**：Rodriguez M, et al.
**摘要**：研究利用重组GAGE10蛋白开发ELISA检测方法，用于分析黑色素瘤患者血清中的GAGE10自身抗体水平。结果显示，高抗体滴度与晚期疾病进展和免疫检查点抑制剂治疗反应相关。
---
**提示**：GAGE家族蛋白(如GAGE10)研究主要集中在肿瘤特异性表达及免疫原性领域，重组蛋白的制备常服务于抗原表位筛选、抗体开发或免疫机制研究。建议通过PubMed或Google Scholar以关键词“GAGE10 recombinant”、“GAGE cancer antigen”进一步检索近期文献。
Recombinant human GAGE10 protein is derived from the G antigen (GAGE) family, a group of cancer-testis antigens (CTAs) primarily expressed in germline cells and aberrantly activated in various cancers. The GAGE family, located on the X chromosome (Xp11.4-Xp11.23), comprises multiple paralogs, including GAGE1 to GAGE10. characterized by conserved sequences encoding small, highly basic proteins. GAGE10. a member of this family, shares structural features such as a conserved C-terminal domain and variable N-terminal regions, though its specific functional motifs remain under investigation.
In normal tissues, GAGE10 expression is restricted to immune-privileged sites like testes but is epigenetically silenced in somatic cells. However, it becomes reactivated in malignancies such as melanoma, lung, breast, and ovarian cancers, correlating with advanced tumor stages and poor prognosis. This ectopic expression is linked to promoter demethylation, a hallmark of many CTAs. GAGE10 is implicated in tumorigenesis by promoting immune evasion, enhancing cell proliferation, and inhibiting apoptosis, possibly through interactions with p53 or ubiquitin pathways.
Research on recombinant GAGE10 focuses on its role in cancer immunotherapy. As a tumor-associated antigen, it can elicit cytotoxic T-cell responses, making it a potential target for vaccines or adoptive T-cell therapies. However, its low immunogenicity and heterogeneous expression in tumors pose challenges. Recombinant GAGE10 protein is also used to study autoimmune responses, given its cross-reactivity with autoantibodies in certain disorders. Current studies aim to unravel its molecular interactions and evaluate its utility as a diagnostic biomarker or therapeutic target.
×
